It's a Family Affair: Lower GI Functional Disorders

Philip Schoenfeld, MD, MSEd, MSc (Epi) Editor-in-Chief,Evidence-Based GI: An ACG Publication Chief (Emeritus)-Gastroenterology Section John D. Dingell VA Medical Center, Detroit, MI

Disclosures

- Consultant:
 - AbbVie, Ardelyx, Exact, Ironwood, Salix, Sanofi, Phathom,
- Speaker:
 - AbbVie, Ardelyx, Ironwood, Phathom









- Monthly online ACG publication. Blast e-mail sent mid-month. Issues archived at ACG website.
- Summarizes important GI clinical research recently published in non-GI journals, including NEJM, JAMA, Lancet, etc.
- Each summary provides structured abstract and expert commentary
- Designed to be read on your phone
- Weekly podcasts and tweetorials



Clinical take-aways and evidence-based summaries of articles in GI, Hepatology & Endoscopy



EVIDENCE-BASED GI AN ACG PUBLICATION

Apple Podcasts

Clinical take-aways and evidence-based summaries of articles in GI, Hepatology & Endoscopy



You can subscribe and download episodes via:



Each issue is available on the <u>ACG website</u>. Log in with your ACG Single Sign-on account to access content.



Disposable Elevator Caps for Duodenoscopes Decrease Persistent Bacterial Contamination Without Hindering Technical ERCP Performance: The ICECAP Trial Shria Kumar, MD, MSCE

G Listen to the audio summary

In this multi-center randomized control trial from Canada of 518 patients undergoing endoscopic retrograde cholangiopancreatography, using duodenoscopes with disposable caps vs standard design scopes reduced persistent microbial contamination after standard disinfection (3.8% vs 11.2%, p = 0.004, relative risk = 0.34, 95% CI: 0.16-0.75) with no differences in performance (technical success: 94.6% vs 90.7%).



Clinical take-aways and evidence-based summaries of articles in GI, Hepatology & Endoscopy



May 2023

TABLE OF CONTENTS

1//ENDOSCOPY

Disposable Elevator Caps for Duodenoscopes Decrease Persistent Bacterial Contamination Without Hindering Technical ERCP Performance: The ICECAP Trial Shria Kumar MD, MSCE

6// ENDOSCOPY

Over-the-Scope Clips Decrease Non-Variceal Upper GI Bleeding vs Standard Endoscopic Treatment... In the Right Patient Jennifer Kolb, MD, MS

12//LIVER

Prophylactic Antibiotics Do Not Improve Mortality in Severe Alcoholic Hepatitis Treated with Corticosteroids Philip Schoenfeld, MD, MSEd, MSc (Epi)

Clinical take-aways and evidence-based summaries of articles in GI, Hepatology & Endoscopy

Tenapanor (IBSRELA) for Treatment of IBS-C: Effective Over 26 Weeks



Philip Schoenfeld, MD, MSEd, MSc (Epi)

Chief (Emeritus)-Gastroenterology Section, John D. Dingell VA Medical Center, Detroit, MI

Philip Schoenfeld, MD, MSEd, MSc (Epi) Editor-in-Chief

This article reviews Chey WD, Lembo A, Yang Y, Rosenbaum DP. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome with Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2). Am J Gastroenterol 2021; 116: 1294-1303. https://doi.org/10.14309/ajg.000000000001056


Correspondence to Philip Schoenfeld, MD, MSEd, MSc (Epi), Editor-in-Chief. Email: EBGI@gi.org

Tweetorial provided by: Romy Chamoun, MD RomyChamoun EBGI Ambassador PGY-3, Lankenau Medical Center





- Blocks NHE3
- FDA-approved for IBS-C
- Minimally absorbed
- Blocks dietary sodium absorption, decreases intestinal permeability and visceral hypersensitivity (animal studies)
- 50mg po bid before breakfast and dinner



Clinical take-aways and evidence-based summaries of articles in GI, Hepatology & Endoscopy

Adapted from:

Chey, W; Lembo, A. J.; Yang, Y; Rosenbaum, D.P. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2), The American Journal of Gastroenterology: June 2021 - Volume 116 - Issue 6 - p 1294-1303 doi:10.14309/ajg.00000000001056

Key Study Definitions

✓Weekly combined response : In average weekly worst abdominal pain of ≥30.0% from baseline

Image: of ≥1 weekly complete spontaneous bowel movements (CSBM) from baseline

6/12-week combined responder rate:
 % of pts who had a weekly combined response for at least 6/12 weeks.

Key Study Endpoints

ÖPrimary Endpoint:

The 6/12-week combined rate.

Key Secondary Endpoint:


- 6/12-week CSBM and abdominal pain responder



Clinical take-aways and evidence-based summaries of articles in GI, Hepatology & Endoscopy

Adapted from:

Chey, W; Lembo, A. J.; Yang, Y; Rosenbaum, D.P. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2), The American Journal of Gastroenterology: June 2021 - Volume 116 - Issue 6 - p 1294-1303 doi: 10.14309/ajg.0000000000001056






Figure 2. Weekly change in CSBMs (A) and abdominal pain (B).



Clinical take-aways and evidence-based summaries of articles in GI, Hepatology & Endoscopy

My Practice

Inadequate relief w/ initial course of a guanylate cyclase-C agonist (linaclotide or plecanatide)

Tenapanor 50 mg po bid (with breakfast and dinner)

<u>Tips:</u>

- Combine Tenapanor + peppermint oil capsules PRN for cramping
- Combine with neuromodulator: prefer duloxetine 30-60mg daily in IBS-C
- Refer to dietician for instruction in low-FODMAP diets



Clinical take-aways and evidence-based summaries of articles in GI, Hepatology & Endoscopy

It's a Bad "Prep" Even Though the Patient Took It Correctly: Consider 15 mg Bisacodyl plus 4-Liter PEG Split Prep Before Next Colonoscopy



Editor-in-Chief

Philip Schoenfeld, MD, MSEd, MSc (Epi)

Chief (Emeritus)-Gastroenterology Section, John D. Dingell VA Medical Center, Detroit, MI

This article reviews Sey MSL, Von Renteln D, Sultanian R, et al. A Multicenter Randomized Controlled Trial Comparing Bowel Cleansing Regimens for Colonoscopy After Failed Bowel Preparation. Clin Gastroenterol Hepatol 2022; In Press. Tweetorial provided by: Zubair Khan, MD @zubairkhan254 Our first EBGI Ambassador PGY-6, University of Texas at

Houston



AMERICAN COLLEGE OF GASTROENTEROLOGY

- <u>Risk Factors for colonic dysmotility and inadequate</u> bowel preparation despite compliance
- > Obesity
- Current opioid use
- Diabetes mellitus
- History of using constipation treatments
- Current use of anticholinergics (including TCA)
- ✤ In non-compliant patient
- Additional patient education is more helpful than prescribing supratherapeutic regimen.

*	Risk Factors for colonic dysmotility and inadequate bowel preparation despite compliance	Prior Trials with Bowel Preparations	
	Obesity	Gimeno-Garcia et al. Am J Gastroenterol 2017; 112: 951-58.	
	Current opioid use	• 10 mg bisacodyl on the day before the procedure + a	
	Diabetes mellitus	low-residue diet for 3 days pre-procedure.	
\succ	History of using constipation treatments	 4L PEG-3350 as split-prep vs 2L PEG + ascorbic acid 	
≻	Current use of anticholinergics (including TCA)	as split-prep	
		 4L PEG-3350-superior for adequate bowel cleansing 	
*	In non-compliant patient	(81.1% vs 67.4%, P< 0.01, ITT analysis)	
\succ	Additional patient education is more helpful than		
	prescribing supratherapeutic regimen.	→ Does not answer if supratherapeutic purgative regimens	
		are more effective!	

- No prior RCT assessing patients who successfully completed 4L PEG split-prep but still had inadequate cleansing.
- Multi-center, single-blind RCT
- Intervention: 4L PEG split prep + 15mg bisacodyl (taken at 2pm on day before scope) vs 6L PEG split prep + 15mg bisacodyl
- Outcome: Adequate bowel prep based on BBPS <u>>6</u> with <u>>2</u> in each segment
- Patient Demographics: 37% obese, 41% with IBS-C or CIC, 10% on opioids. Prior bowel prep: 35% used 4L PEG; 38% used 2L PEG; 12% used sodium picosulfate

Clinical take-aways and evidence-based summaries of articles in GI, Hepatology & Endoscopy

It's a Bad "Prep" Even Though the Patient Took It Correctly: Consider 15 mg Bisacodyl plus 4-Liter PEG Split Prep Before





Outcome		Split-dose 4L + bisacodyl (n = 97)	Split-dose 6L + bisacodyl (n = 99)	<i>P</i> -value
Adequate cleansing	Defined as BBPS ≥ 6	83 (91.2%)	78 (87.6%)	0.44
	Defined as adequate to identify polyps > 5mm	82 (91.1%)	76 (85.4%)	0.24
Secondary endpoints	Cecal intubation rate, n (%)	87 (96.7%)	82 (92.1%)	0.19
	Adenoma detection rate, n (%)	34 (37.4%)	28 (31.5%)	0.41
Adherence	Diet + consumed 100% of prep	67 (81.7%)	53 (68.0%)	0.05
	Diet + consumed 80% of prep	71 (86.6%)	57 (73.1%)	0.03

Adapted from Sey MSL et al. Clin Gastroenterol Hepatol 2022.

Clinical take-aways and evidence-based summaries of articles in GI, Hepatology & Endoscopy It's a Bad "Prep" Even Though the Patient Took It Correctly: Consider 15 mg Bisacodyl plus 4-Liter PEG Split Prep Before Next Colonoscopy

My Practice-Before This Trial						
Reactive prescription: prior inadequate bowel cleansing		Proactive Prescription: any patient with 2 or more risk factors for inadequate cleansing				
6L PEG-3350 split-prep with 4L PEG consumed between 6 and 10 PM on the night before the procedure and 2L taken 4-6 hours before colonoscopy.						
Adequate cleansing Successes per BBPS						
	87.7%	91.5%				
Remember, patient education is the preferred intervention in non- compliant patients.						



Clinical take-aways and evidence-based summaries of articles in GI, Hepatology & Endoscopy It's a Bad "Prep" Even Though the Patient Took It Correctly: Consider 15 mg Bisacodyl plus 4-Liter PEG Split Prep Before Next Colonoscopy

My Practice-Be		
Reactive prescription: prior inadequate bowel cleansing	Proactive Prescription: any patient with 2 or more risk factors for inadequate bowel cleansing	Switched to 4L PEG split-prep +
6L PEG-3350 split-prep with 4L PEG the night before the procedure and 2L	15 mg bisacodyl at 2pm on day before scope	
Adequate cleansing S		
87.7%	91.5%	
Remember, patient education is t compliant		



Clinical take-aways and evidence-based summaries of articles in GI, Hepatology & Endoscopy

Vibrating Capsules for Chronic Constipation: The New Non-Pharmacologic Approach



Philip Schoenfeld, MD, MSEd, MSc (Epi)

Chief (Emeritus), Gastroenterology Section, John D. Dingell VA Medical Center, Detroit, MI.

Editor-in-Chief


This summary reviews Rao S, Quigley EMM, Chey WD, et al. Randomized Placebo-Controlled Phase 3 Trial of Vibrating Capsule for Chronic Constipation. Gastroenterology 2023; In Press. doi.org/10/1053/j.gastro.2023.02.013

Carl Kay, MD 🔰 @CarlKayMD **PGY-5, SAUSHEC** Anoushka Dua, MD @anoushkaduaMD PGY-3, UCLA

Tweetorial Provided by:



Clinical take-aways and evidence-based summaries of articles in GI, Hepatology & Endoscopy "Vibrating Capsules for Chronic Constipation: The New Non-Pharmacologic Approach" Summary of Rao et al. *Gastroenterology* 2023



Importance

Clinical take-aways and evidence-based summaries of articles in GI, Hepatology & Endoscopy

Vibrating Capsules for Chronic Constipation: The New Non-Pharmacologic Approach" Summary of Rao et al. Gastroenterology 2023

Chronic Idiopathic Constipation (CIC)

² of the following: <3 💩 per wk</p> Straining >25% Hard 25% • maneuver >25%


- Rare loose 4 without laxatives
- Blockage sensation >25%
- Incomplete sensation >25%

Spontaneous BM (SBM)

BM w/o use of rescue medicine in preceding 48 hrs & w/o use of digital maneuvers


Complete Spontaneous BM (CSBM)

SBM <u>plus</u> subject report of feeling complete evacuation



Definitions & Endpoints

"Vibrating Capsules for Chronic Constipation: The New Non-Pharmacologic Approach" Summary of Rao et al. *Gastroenterology* 2023




Mode 1: starts vibrating from 12PM next day Mode 2: starts vibrating from 6AM next day

Study Design

Clinical take-aways and evidence-based summaries of articles in GI, Hepatology & Endoscopy "Vibrating Capsules for Chronic Constipation: The New Non-Pharmacologic Approach" Summary of Rao et al. *Gastroenterology* 2023


Effect of Vibrating Capsule on CSBM, Primary Outcomes



Results

Clinical take-aways and evidence-based summaries of articles in GI, Hepatology & Endoscopy

Vibrating Capsules for Chronic Constipation: The New Non-Pharmacologic Approach" Summary of Rao et al. *Gastroenterology* 2023



Linaclotide for Pediatric Functional Constipation-First prescription treatment for pediatic FC!

• Double-blind, placebo-controlled, Phase 3 RCT


• 328 pediatric patients (6-17 years old) with modified ROME III criteria for functional constipation (mean SBM/week: 1.2)

• Intervention: 72 ucg linaclotide vs placebo X 12 weeks

• Primary Outcome: Increase in SBMs/week

Di Lorenzo C, Nurko S, et al. Gastro 2023; P145

Linaclotide for Pediatric Functional Constipation




-Increase in 12-week SBM frequency significantly greater with linaclotide: 2.22 vs 1.05, p = 0.0001

-Significant improvement in stool consistency, based on Bristol stool scale, with linaclotide vs placebo

Adverse events: diarrhea < 5% and < 2% discontinued drug due to diarrhea

Di Lorenzo C, Nurko S, et al. Gastro 2023; P145

Trend for Larger Increase in SBM/week in linaclotide-treated 6-11 year olds vs linaclotide-treated 12-17 year olds



My Practice: Use 145 ucg dose for selected 12-17 year olds with functional constipation. Most likely approved for use in summer 2023. Probably will be approved for long-term use.